FL S0840

Creates s. 385.2021, F.S., requiring cancer clinical trial programs to inform prospective patients that reimbursement for travel and ancillary expenses is available based on financial need for both participants and their caregivers

Establishes that reimbursement offers for trial-related expenses are not considered inducements for participation, provided they are not coercive or exert undue influence

Authorizes corporations, individuals, foundations, health care providers, and other stakeholders to offer financial assistance through third-party nonprofit corporations and public charities to support expense reimbursements for cancer clinical trial participants

Requires third-party organizations offering reimbursement programs to secure informed consent from patient subjects, including disclosure of financial eligibility guidelines and the reimbursement process

Directs the Department of Health to review and approve reimbursement programs that comply with federal regulations and appropriately cover ancillary and travel expenses, and to adopt implementing rules